Lutetium-177 PSMA Radioligand (Pluvicto)

Type: drug

Status: FDA/EMA Approved

Developer: Novartis

Breakthrough Summary

No summary available.

Mechanism of Action

Radioactive molecule targeting PSMA on prostate cancer cells

Year: 2022+